Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Greetings, and welcome to the INmune Bio Second Quarter 2025 Earnings Call. [Operator Instructions] As a reminder, this conference is being ...

Explore INmune Bio's Fair Values from the Community and select yours. Even when a business is losing money, it's possible for shareholders to make money if they buy a good busines ...

Company to Host Conference Call Today, August 7th, at 4:30pm ETBOCA RATON, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company ...

INmune Bio Inc. (NASDAQ:INMB) saw its stock jump 28% on Monday after announcing that its Phase I/II trial evaluating INKmune™ ...

Following the announcement of TNF inhibitor, INmune Bio Inc. stock surged by 24.72% in after-hours trading on Friday.

INmune Bio has a total of 14,932,638 shares outstanding, of which 1,811,241 shares are owned by insiders. The founders and insiders thereby retain significant ownership.

The latest update is out from Inmune Bio ( (INMB) ).

INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.

(Reuters) -INmune Bio said on Monday its experimental Alzheimer's drug failed to improve cognitive functions in patients with early stages of the mind-robbing disease in a mid-stage study, sending ...

About INmune Bio INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.

Both Cassava Sciences and INmune Bio have brought impressive results on neuroinflammation and neurodegeneration. I expect INmune Bio’s XPro to yield impressive results in its phase 2 trials like ...